<DOC>
	<DOCNO>NCT02339337</DOCNO>
	<brief_summary>This open label , randomized-controlled , comparative trial . HBV HCV dually infect patient negative hepatitis B e antigen ( HBeAg ) enrol study . The definition HBV HCV dual infection include seropositivity HCV antibody ( anti-HCV ) HBsAg 6 month , together positive serum HCV RNA . Eligible subject randomize 2 group treatment initiation . Subjects randomize genotype guide therapy ( GGT ) group receive Peg-IFN standard dose RBV ( 1200 mg/day ) 48 week subject infect HCV genotype 1 Peg-IFN low dose RBV ( 800 mg/day ) 24 week subject infect HCV genotype 2/3 ; patient follow 6 month . For subject randomize response guide therapy ( RGT ) group , duration Peg-IFN RBV therapy abbreviate 24 week subject HCV genotype 1 , pre-treatment low viral load ( LVL , &lt; 400000 IU/mL ) RVR ( define asHCV RNA &lt; 50 IU/mL 4th week therapy ) ; duration 16 week subject HCV genotype 2/3 RVR .</brief_summary>
	<brief_title>A Pilot Study To Evaluate Efficacy Response Guided Therapy Peginterferon Alfa Plus Ribavirin Treatment Patients With HCV/HBV Co-Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>seropositivity HCV antibody ( antiHCV ) HBsAg 6 month , together positive serum HCV RNA . negative HBeAg serum alanine aminotransferase ( ALT ) level 110fold upper limit normal ( ULN ) treatment naive previously fail interferon monotherapy . decompensated liver disease ( ChildPugh score ≥ 7 ) Pregnant breastfeed woman serum creatinine ≥ 2 mg/dL evidence alcoholism drug abuse know disease suitable PegIFN therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>